Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C13H7ClF2INO2 |
| Molecular Weight | 409.554 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CC=C(F)C(F)=C1NC2=CC=C(I)C=C2Cl
InChI
InChIKey=XCNBGWKQXRQKSA-UHFFFAOYSA-N
InChI=1S/C13H7ClF2INO2/c14-8-5-6(17)1-4-10(8)18-12-7(13(19)20)2-3-9(15)11(12)16/h1-5,18H,(H,19,20)
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
853921
Created by
admin on Sat Dec 16 18:58:18 GMT 2023 , Edited by admin on Sat Dec 16 18:58:18 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID80435811
Created by
admin on Sat Dec 16 18:58:18 GMT 2023 , Edited by admin on Sat Dec 16 18:58:18 GMT 2023
|
PRIMARY | |||
|
C183111
Created by
admin on Sat Dec 16 18:58:18 GMT 2023 , Edited by admin on Sat Dec 16 18:58:18 GMT 2023
|
PRIMARY | |||
|
11998
Created by
admin on Sat Dec 16 18:58:18 GMT 2023 , Edited by admin on Sat Dec 16 18:58:18 GMT 2023
|
PRIMARY | |||
|
4RZD8LK83V
Created by
admin on Sat Dec 16 18:58:18 GMT 2023 , Edited by admin on Sat Dec 16 18:58:18 GMT 2023
|
PRIMARY | |||
|
10112191
Created by
admin on Sat Dec 16 18:58:18 GMT 2023 , Edited by admin on Sat Dec 16 18:58:18 GMT 2023
|
PRIMARY | |||
|
303175-44-2
Created by
admin on Sat Dec 16 18:58:18 GMT 2023 , Edited by admin on Sat Dec 16 18:58:18 GMT 2023
|
PRIMARY | |||
|
KL-189
Created by
admin on Sat Dec 16 18:58:18 GMT 2023 , Edited by admin on Sat Dec 16 18:58:18 GMT 2023
|
PRIMARY | |||
|
300000026756
Created by
admin on Sat Dec 16 18:58:18 GMT 2023 , Edited by admin on Sat Dec 16 18:58:18 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (METABOLITE ACTIVE)
